论文部分内容阅读
最近在美国加州的Anaheim召开了美国心脏协会年会。与会者的注意力主要集中在药学科学的新发明上。这些发明在临床实践中,对心脏病的治疗发挥了作用。特别值得提到的是,一批新的降脂药物的使用,比如LEovastatin是一种3-羟基-3-甲基戊二酰辅酶A的抑制剂。这一药品的发明被认为是开辟了治疗动脉粥样硬化性心脏病的新路子。据预测,将有6％的
Recently held an annual meeting of the American Heart Association in Anaheim, California, USA. Attendees’ attention focused mainly on the new invention of pharmaceutical science. These inventions have played a role in the treatment of heart disease in clinical practice. Of particular note is the use of a number of new lipid-lowering drugs, such as LEovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA. The invention of this drug is believed to have opened up new avenues for the treatment of atherosclerotic heart disease. It is predicted that there will be 6%